TBIO Insider Trading Activity and SEC Form 4 Filings
TBIO insider trading summary
No open-market insider purchases or sales of Telesis Bio Inc. (TBIO) have been reported on SEC Form 4 in the past 12 months.
Latest TBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 4, 2023 | Todd Robert Nelson | President & CEO | Sell | $7K (2,575 @ $2.83) |
| May 4, 2023 | Daniel Glenn Gibson | Chief Technology Officer | Sell | $3K (1,190 @ $2.83) |
| May 4, 2023 | Rob Cutler | Chief Legal Officer | Sell | $3K (1,174 @ $2.83) |
| Sep 14, 2021 | Jean Francois Formela | Director | Sell | $78.1M (2,055,063 @ $38.00) |
| Sep 14, 2021 | Owen Hughes | Director | Sell | $1.1M (29,860 @ $38.00) |
| Sep 14, 2021 | Ronald C Renaud JR | Chief Executive Officer | Sell | $15.6M (409,913 @ $38.00) |
| Sep 14, 2021 | Ronald C Renaud JR | Chief Executive Officer | Sell | $1.6M (40,909 @ $38.00) |
| Sep 14, 2021 | Ronald C Renaud JR | Chief Executive Officer | Sell | $19.1M (503,231 @ $38.00) |
| Sep 14, 2021 | Sanofi | 10% Owner | Buy | $1.96B (51,467,612 @ $38.00) |
| Sep 14, 2021 | Sanofi | 10% Owner | Buy | $779.6M (20,515,985 @ $38.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.